Avidity Biosciences Receives Positive Feedback from FDA for Del-Zota in DMD44 Treatment Submission Planned for Early 2026
Avidity Biosciences' Progress with Del-Zota
On October 13, 2025, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical firm at the forefront of RNA therapeutic innovations, announced a significant milestone in its mission to offer transformative treatments for rare diseases. The company has recently concluded a fruitful pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA) regarding its upcoming submission for delpacibart zotadirsen (del-zota). This potential treatment focuses on customers suffering from Duchenne muscular dystrophy (DMD), specifically targeting those with gene mutations that align with exon 44 skipping (DMD44).
Del-zota has earned the FDA's Breakthrough Therapy designation, emphasizing its significance in addressing an unmet medical need within the DMD patient population. The expected BLA submission has been scheduled for Q1 2026, a slight shift from the previously anticipated timeline of late 2025. This adjustment allows Avidity to furnish the FDA with more comprehensive data related to the necessary chemistry, manufacturing, and controls (CMC) package at the time of submission.
Sarah Boyce, President and CEO of Avidity Biosciences, expressed optimism post-meeting, highlighting the collaborative nature of the discussions with the FDA. She shared, "Our recent meeting with the FDA was highly collaborative and provided a clear path for our BLA submission. We’re grateful for the guidance on the CMC data necessary for submission, and we believe this alignment will facilitate a successful BLA process." Boyce emphasized the urgency of this matter, stating, "For boys and young men living with DMD, every moment is critical. The accelerated approval pathway in the U.S. presents an opportunity to bring del-zota to those in dire need as swiftly as possible."
Avidity is confident in del-zota’s potential to transform the lives of DMD patients and is not only gearing up for its BLA submission but is also preparing for a confirmatory study that will support the drug’s full global approval. This commitment to advancing treatment options for rare diseases is grounded in its proprietary RNA therapeutic approach known as Antibody Oligonucleotide Conjugates (AOCs™)—a novel class of RNA therapeutics designed to combine the targeting mechanism of monoclonal antibodies with the precise action of oligonucleotide therapies. Avidity stands at the forefront of the RNA field, achieving a landmark accomplishment by successfully targeting RNA delivery into muscle tissue, a feat previously considered unfeasible with existing RNA therapeutic methods.
Avidity's pipeline is ambitious, with clinical trials underway for three distinct rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). Additionally, the company is advancing two wholly-owned candidates, specifically aimed at rare genetic cardiomyopathies, reaffirming its commitment to expand AOCs beyond muscular dystrophies into other urgent healthcare arenas.
For a firm so dedicated to its mission of enhancing patient lives, Avidity continues to build crucial partnerships that will broaden the outreach of its innovative AOC platform. With a solid foundation in place, Avidity Biosciences is well-prepared to navigate the complexities of drug development and regulatory approval, keeping the needs of patients at the forefront of its endeavors. As the anticipation builds toward the BLA submission in early 2026, stakeholders remain hopeful for a favorable outcome that would signify a giant leap forward in the fight against Duchenne muscular dystrophy.
For more information about Avidity Biosciences and its groundbreaking work, visit Avidity Biosciences' Website or engage with them on LinkedIn and Twitter.
On October 13, 2025, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical firm at the forefront of RNA therapeutic innovations, announced a significant milestone in its mission to offer transformative treatments for rare diseases. The company has recently concluded a fruitful pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA) regarding its upcoming submission for delpacibart zotadirsen (del-zota). This potential treatment focuses on customers suffering from Duchenne muscular dystrophy (DMD), specifically targeting those with gene mutations that align with exon 44 skipping (DMD44).
Del-zota has earned the FDA's Breakthrough Therapy designation, emphasizing its significance in addressing an unmet medical need within the DMD patient population. The expected BLA submission has been scheduled for Q1 2026, a slight shift from the previously anticipated timeline of late 2025. This adjustment allows Avidity to furnish the FDA with more comprehensive data related to the necessary chemistry, manufacturing, and controls (CMC) package at the time of submission.
Sarah Boyce, President and CEO of Avidity Biosciences, expressed optimism post-meeting, highlighting the collaborative nature of the discussions with the FDA. She shared, "Our recent meeting with the FDA was highly collaborative and provided a clear path for our BLA submission. We’re grateful for the guidance on the CMC data necessary for submission, and we believe this alignment will facilitate a successful BLA process." Boyce emphasized the urgency of this matter, stating, "For boys and young men living with DMD, every moment is critical. The accelerated approval pathway in the U.S. presents an opportunity to bring del-zota to those in dire need as swiftly as possible."
Avidity is confident in del-zota’s potential to transform the lives of DMD patients and is not only gearing up for its BLA submission but is also preparing for a confirmatory study that will support the drug’s full global approval. This commitment to advancing treatment options for rare diseases is grounded in its proprietary RNA therapeutic approach known as Antibody Oligonucleotide Conjugates (AOCs™)—a novel class of RNA therapeutics designed to combine the targeting mechanism of monoclonal antibodies with the precise action of oligonucleotide therapies. Avidity stands at the forefront of the RNA field, achieving a landmark accomplishment by successfully targeting RNA delivery into muscle tissue, a feat previously considered unfeasible with existing RNA therapeutic methods.
Avidity's pipeline is ambitious, with clinical trials underway for three distinct rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). Additionally, the company is advancing two wholly-owned candidates, specifically aimed at rare genetic cardiomyopathies, reaffirming its commitment to expand AOCs beyond muscular dystrophies into other urgent healthcare arenas.
For a firm so dedicated to its mission of enhancing patient lives, Avidity continues to build crucial partnerships that will broaden the outreach of its innovative AOC platform. With a solid foundation in place, Avidity Biosciences is well-prepared to navigate the complexities of drug development and regulatory approval, keeping the needs of patients at the forefront of its endeavors. As the anticipation builds toward the BLA submission in early 2026, stakeholders remain hopeful for a favorable outcome that would signify a giant leap forward in the fight against Duchenne muscular dystrophy.
For more information about Avidity Biosciences and its groundbreaking work, visit Avidity Biosciences' Website or engage with them on LinkedIn and Twitter.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.